Cytokines involved in graft-versus-host disease
- PMID: 7705747
Cytokines involved in graft-versus-host disease
Abstract
Graft-versus-host disease (GVHD) is one of the major complications which should be resolved to improve the survival rates in allogeneic bone marrow transplantation (BMT). Recently, several cytokines have been identified, suggesting that they form a cytokine network and play an important role in immune system and hematopoiesis. Among several cytokines, it has been reported that tumor necrosis factor alpha (TNF alpha) and interleukin-6 (IL-6) are mainly involved in GVHD. In the present report, we analyzed the role of cytokines in GVHD. When we measured serum cytokine levels, IL-6, interferon gamma (IFN gamma), and TNF alpha levels were increased prior to the onset of acute GVHD. For chronic GVHD, a similar pattern of cytokine increment was observed. Interestingly, these cytokines appeared to interact synergistically to induce clinical GVHD, suggesting that none of those cytokines does not function solely. Reverse transcriptase-polymerase chain reaction (RT-PCR) showed that increased IL-1 beta mRNA expression was also observed in acute GVHD in addition to increased IL-6 and TNF alpha mRNA expressions. Unexpectedly, no increased IL-2 levels were observed in both assays. In hyperacute GVHD, only IL-6 level was increased. However, in vivo administration of IL-6 into allogeneic bone marrow chimeras did not induce severe GVHD. Therefore, some other factors also appeared to be involved in inducing hyperacute GVHD. Furthermore, it is important to consider the role of inhibitory cytokines such as transforming growth factor beta (TGF beta) or IL-10.
Similar articles
-
Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.Bone Marrow Transplant. 1994 Jun;13(6):745-51. Bone Marrow Transplant. 1994. PMID: 7920309
-
IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.Transplantation. 1994 Dec 27;58(12):1385-93. Transplantation. 1994. PMID: 7809932
-
Cytokine expression in human cutaneous chronic graft-versus-host disease.Bone Marrow Transplant. 1996 Jun;17(6):1085-92. Bone Marrow Transplant. 1996. PMID: 8807119
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Cytokines as mediators of graft-versus-host disease.Bone Marrow Transplant. 1988 May;3(3):193-7. Bone Marrow Transplant. 1988. PMID: 3048486 Review.
Cited by
-
Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.Blood Adv. 2023 May 23;7(10):2181-2195. doi: 10.1182/bloodadvances.2022008495. Blood Adv. 2023. PMID: 36780582 Free PMC article.